Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transfer factor therapy in ataxia--telangiectasia.

A I Berkel, F Ersoy, L B Epstein

    Clinical and Experimental Immunology
    |September 1, 1977
    PubMed
    Summary

    Transfer factor therapy for ataxia-telangiectasia patients showed no clinical improvement in infections. However, it enhanced cellular immune responses, including skin-test reactivity and migration inhibitory factor (MIF) production, despite unchanged lymphocyte counts.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Oxidative stress and asymmetric dimethylarginine is independently associated with carotid intima media thickness in peritoneal dialysis patients.

    American journal of nephrology·2007
    Same author

    Mutations of chronic granulomatous disease in Turkish families.

    European journal of clinical investigation·2007
    Same author

    Skewing of X-chromosome inactivation in three generations of carriers with X-linked chronic granulomatous disease within one family.

    European journal of clinical investigation·2006
    Same author

    Assessment and comparison of endothelial function between dialysis and kidney transplant patients.

    Transplantation proceedings·2006
    Same author

    Influence of inflammation on the relation between markers of iron deficiency in renal replacement therapy.

    Transplantation proceedings·2004
    Same author

    Seroprevalence of antibodies to legionella pneumophila in hemodialysis patients.

    Transplantation proceedings·2004

    Area of Science:

    • Immunology
    • Clinical Medicine
    • Genetics

    Background:

    • Ataxia-telangiectasia (A-T) is a rare, inherited neurodegenerative disorder with severe immunodeficiency.
    • Patients with A-T often suffer from recurrent infections, highlighting the need for effective immunotherapies.

    Purpose of the Study:

    • To evaluate the immunomodulatory effects of transfer factor in patients with ataxia-telangiectasia.
    • To assess clinical outcomes, particularly infection rates, following transfer factor administration.

    Main Methods:

    • Weekly administration of transfer factor for 2 months in four A-T patients.
    • Assessed absolute lymphocyte counts, T-cell rosettes, antibody titers to EBV, skin-test reactivity, migration inhibitory factor (MIF) production, and serum interferon levels.
    • Monitored clinical improvement in infections.

    Main Results:

    • Transfer factor did not alter lymphocyte counts, T-cell rosettes, or EBV antibody titers.
    • Significant conversion of skin-test reactivity and MIF production to various antigens was observed.
    • A dissociation was noted between blastic transformation response, skin-test responses, and MIF production.
    • Serum interferon levels remained low post-therapy.
    • No clinical improvement in infections was reported.

    Conclusions:

    • Transfer factor can modulate cellular immune responses in ataxia-telangiectasia patients, evidenced by improved skin-test reactivity and MIF production.
    • Despite immunomodulatory effects, transfer factor did not improve clinical outcomes regarding infections or affect key immunological markers like lymphocyte counts.
    • Further research is needed to understand the dissociation in immune responses and explore alternative therapeutic strategies for A-T.

    Related Experiment Videos